Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment.

Alzheimers Dement (N Y) 2020 22;6(1):e12002. Epub 2020 Mar 22.

Broad Institute of Harvard and MIT Cambridge Massachusetts USA.

Introduction: The safety of predicting conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia using apolipoprotein E () genotyping is unknown.

Methods: We randomized 114 individuals with MCI to receive estimates of 3-year risk of conversion to AD dementia informed by genotyping (disclosure arm) or not (non-disclosure arm) in a non-inferiority clinical trial. Primary outcomes were anxiety and depression scores. Secondary outcomes included other psychological measures.

Results: Upper confidence limits for randomization arm differences were 2.3 on the State Trait Anxiety Index and 0.5 on the Geriatric Depression Scale, below non-inferiority margins of 3.3 and 1.0. Moreover, mean scores were lower in the disclosure arm than non-disclosure arm for test-related positive impact (difference: -1.9, indicating more positive feelings) and AD concern (difference: -0.3).

Discussion: Providing genetic information to individuals with MCI about imminent risk for AD does not increase risks of anxiety or depression and may provide psychological benefits.

Download full-text PDF

Source
http://dx.doi.org/10.1002/trc2.12002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087414PMC
March 2020

Publication Analysis

Top Keywords

mild cognitive
8
disclosure arm
8
non-disclosure arm
8
cognitive impairment
8
anxiety depression
8
individuals mci
8
arm non-disclosure
8
arm
5
clinical trial
4
non-inferiority clinical
4
test-related positive
4
arm test-related
4
trial primary
4
3-year risk
4
lower disclosure
4
arm non-inferiority
4
risk conversion
4
dementia informed
4
genotyping disclosure
4
impact difference
4

Similar Publications